Invivyd, Inc. (IVVD) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Invivyd, Inc. is a biopharmaceutical company focused on developing monoclonal antibodies for viral infectious diseases, primarily SARS-CoV-2. The company's lead product, PEMGARDA (pemivibart), received Emergency Use Authorization (EUA) in March 2024 for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals. The company is also advancing VYD2311, a next-generation candidate, which recently completed positive Phase 1/2 clinical data.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $11.8 million | $2.3 million | $23.1 million | $2.3 million |
| Net Loss | $(14.7) million | $(47.2) million | $(30.9) million | $(90.7) million |
| Loss Per Share (Basic/Diluted) | $(0.12) | $(0.40) | $(0.26) | $(0.77) |
| Research & Development Expenses | $9.6 million | $30.3 million | $20.2 million | $61.5 million |
| Selling, General & Admin Expenses | $16.6 million | $21.1 million | $33.3 million | $36.0 million |
| Cash and Cash Equivalents (End of Period) | $34.9 million (as of June 30, 2025) | |||
| Accumulated Deficit | $932.9 million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased significantly by $9.5 million in Q2 2025 compared to Q2 2024, driven by commercial sales of PEMGARDA following its April 2024 launch.
- Expense Reduction: Operating expenses decreased substantially. R&D expenses dropped $20.8 million quarter-over-quarter, primarily due to reduced contract costs for the Phase 3 CANOPY trial (pemivibart) and manufacturing costs for VYD2311. SG&A expenses decreased $4.5 million, largely due to a reduction in stock-based compensation expense following the accelerated vesting of a former CEO's options in the prior year.
- Improved Loss Profile: The net loss narrowed significantly from $47.2 million in Q2 2024 to $14.7 million in Q2 2025.
- Cash Position: Cash and cash equivalents decreased from $69.3 million at year-end 2024 to $34.9 million at June 30, 2025, reflecting a net cash burn of $34.4 million in the first half of 2025.
Outlook, Risks, and Contingencies
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. Based on current plans and excluding future revenue or financing, cash reserves are insufficient to fund operations beyond one year from the filing date.
- Financing Needs: The company requires additional funding through equity offerings, debt, grants, or collaborations. A $30 million term loan facility with Silicon Valley Bank was secured in April 2025, but the company has not yet met the revenue milestones required to draw down funds as of June 30, 2025.
- Regulatory Progress: In August 2025, the company announced alignment with the FDA on a rapid pathway for a Biologics License Application (BLA) for VYD2311, potentially requiring only a single Phase 2/3 trial.
- Nasdaq Compliance: The company received notice in April 2025 of non-compliance with Nasdaq's minimum bid price requirement (stock closed below $1.00 for 30 consecutive days). The company has until October 20, 2025, to regain compliance to avoid delisting.
- Contractual Obligations: The company has $25.9 million in remaining noncancelable purchase obligations for commercial manufacturing with WuXi Biologics, due in 2025.
Investor Verification Checklist
- Cash Runway: Verify the timeline for securing additional capital given the "substantial doubt" disclosure and current cash balance of $34.9 million.
- Loan Milestones: Confirm the specific net product revenue milestones required to access the $30 million Silicon Valley Bank term loan facility.
- Nasdaq Status: Monitor the stock price to ensure compliance with the $1.00 minimum bid price requirement by the October 20, 2025 deadline.
- PEMGARDA Sales Trajectory: Assess whether current revenue levels ($11.8M in Q2) are sustainable or if they are subject to significant volatility based on variant susceptibility and EUA conditions.
- VYD2311 Trial Design: Review the finalized protocol for the compact Phase 2/3 trial discussed with the FDA to understand the path to full approval.